Why You Might Have Gained Weight on Wegovy

What the trial data tell us about the minority who don't lose weight

The STEP 1 trial is the foundation of Wegovy's UK licence, but its headline figure (roughly 15% average body weight reduction) comes from the full 68-week run at a 2.4mg maintenance dose. Early in the trial, before participants reached that dose, weight responses were much smaller and highly variable. A subset of participants in placebo-controlled GLP-1 trials consistently show minimal response, and a smaller group report net gain. The NHS patient information for semaglutide is candid that side effects, particularly gastrointestinal ones, can lead some people to eat differently (sometimes more) than expected once nausea settles.

The mechanism matters here. Semaglutide slows gastric emptying and acts on appetite-regulating pathways in the brain. When nausea is acute, calorie intake drops sharply. When nausea fades (which it usually does after a few weeks on a stable dose) appetite can rebound before the brain's hunger signals have fully reset. That window is when compensatory eating can tip the scale upward.

There is also an important distinction between fat mass and overall body weight. If muscle mass falls while fat is lost, the two effects can roughly cancel out on a standard scale. This is more likely in people who reduce activity significantly alongside their dietary changes, and it can produce a reading that looks like plateau or slight gain when body composition is actually shifting.

The titration phase is the period when gains are most likely

A question our prescribers hear most weeks goes something like this: "I've been on Wegovy for a month and I've actually put weight on, is something wrong?" In most cases, the answer is: not yet. The 0.25mg starting dose exists to give the body time to adjust to the medicine, not to suppress appetite at a therapeutic level. At 0.5mg and 1.0mg, the effect on hunger begins to build for many people, but it is still modest compared with the 1.7mg and 2.4mg maintenance doses.

During those early weeks, the nausea that many people experience can temporarily reduce food intake, then lift. If someone responds by eating more normally, or if anxiety about nausea leads them to choose calorie-dense foods that feel "safer" on a queasy stomach (plain biscuits, white bread, soft carbohydrates), the net caloric effect can be a surplus rather than a deficit. The scale moves up, panic sets in, and people sometimes stop treatment before it has had a fair chance to work.

The practical implication is to separate what's happening now from what's likely at maintenance dose. If you are still on a sub-therapeutic dose and have gained a small amount, that picture may change substantially once titration is complete. For context on how Wegovy's dose schedule is structured, the first 24 hours on Wegovy resource covers what to expect as treatment begins. The NICE recommendation for semaglutide (TA875) suggests considering discontinuation only if less than 5% weight loss has occurred after six months on the maintenance dose, not during titration. Source: NICE TA875.

Persistent gain on a maintenance dose: what to look for

If you are established on 2.4mg (or the newer 7.2mg dose, now available following MHRA approval in early 2026) and your weight is climbing, that is a different conversation. Persistent gain on a full maintenance dose points toward one of several possibilities: a medical condition affecting weight regulation that hasn't been assessed; a medicine taken alongside semaglutide that promotes weight gain (certain antidepressants, corticosteroids, insulin, beta-blockers, some antipsychotics); significant change in physical activity; or, less commonly, a primary non-response to this class of medicine.

It is also worth examining what's changed in the wider picture. Weight management over time is covered thoroughly on the weight outcomes on Wegovy page, including why responses shift at different stages of treatment. For some people, the answer lies in what happens after Wegovy, weight regain following discontinuation is well-documented, and if treatment has already stopped, that context changes the analysis entirely. The weight gain after stopping Wegovy page covers that scenario specifically.

For those actively gaining on a current prescription, a clinical review is the right route. Stopping without one risks missing a correctable cause. Tirzepatide (Mounjaro) produces a different hormonal effect through dual GIP and GLP-1 receptor activation, and the SURMOUNT-5 head-to-head trial showed it produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, switching could be worth discussing with a prescriber, though it is a clinical decision, not a simple swap. You can read more about how the two medicines compare on the semaglutide overview page.

When to talk to a prescriber, and what that conversation looks like

Gaining weight on Wegovy is a clinical signal, and it deserves a clinical response rather than self-troubleshooting. Logging your food intake honestly for a week before any review is practically useful, not as self-blame, but as data. So is a note of any other medicines, any changes in sleep, stress, or activity, and when the gain started relative to your dose stage.

The question of whether to continue, increase the dose, switch to a different treatment, or investigate an underlying cause is exactly the kind of thing a GPhC-registered prescriber should work through with you. If you're thinking about your options, whether Wegovy can cause weight gain directly is a related question worth reading alongside this one. Broader context on treatment choices is on the weight loss treatments overview. When you're ready to talk to a clinician, check your eligibility with our prescribers, consultations are free, reviewed the same working day, and carry no obligation.